Pharmacy & Drug Cost Strategies

In the past 24 hours, CMS under the Trump administration has proposed an extension of its prior authorization rules to encompass pharmaceuticals, signaling a potential tightening of drug utilization controls within Medicare and Medicaid that could impact provider workflows and patient access—particularly for high-cost specialty and weight-loss drugs. This move, paired with rising clinician concerns over the rapid integration of weight-loss injections in obesity treatment, underscores mounting tensions between pharmaceutical-driven innovation and cost containment imperatives for ACOs and population health leaders. For further details, see CMS proposes extension of prior authorization rule to cover drugs and how weight-loss injections are changing obesity treatment.